Archive for the ‘Medicine’ Category
Wednesday, July 20th, 2011
Preparing for the drug therapies required to combat tomorrow’s illnesses of high socioeconomic impact
Conference Dates: 4-5th October, 2011
Venue: London, UK
It is now widely known that healthcare systems around the world are already under significant budgetary pressure, with the prognosis for the future looking far from positive. Ageing populations, growing incidents of chronic disease that effect large patient populations, costly acute specialty conditions, expensive treatments for rare-diseases and the widespread use of more effective, yet expensive drugs and technologies are some of the main drivers. Governments are well aware that investing in a healthier population results in a richer and happier population. Medicines that can dramatically improve quality of life can help to keep patients out of expensive hospital care and often back into the workforce as productive members of society.
The economic value of such treatments are often exceptional and easily measurable. Despite years of health reform and cost-containment policy implementation, only some of the symptoms have been treated effectively, but the underlying cause needs urgent attention before costs for payers spiral out of control. There often seems to be a disconnect between what therapies payers and policy makers need and see as public health priorities worthy of investment and what products pharma companies and medical manufacturers are bringing to the market. Drug developers take extreme risks in bringing new drugs to the market, spending over a billion dollars per therapy and investing over 10 years on average in R&D time and still face very high failure rates. This investment needs to be more targeted at least to the areas that payers define as unmet need and of high value for such extreme risks to be worthwhile taking. Considerable progress has been made on both sides, with payers increasingly “scanning horizons” to find out what drugs and devices will affect their budgets in the coming years, whilst manufacturers have paid much more attention to receiving scientific advice from payers earlier in the clinical trials process.
There is also confusion with regards to the definition of “innovation” and how much payers are willing to invest in “innovations”. Novel classes of small and large molecules with exciting mechanisms of action may only have slight therapeutic benefits over existing drugs, whilst “incremental innovations” of older drugs could alternatively also improve outcomes at significantly less cost. A solid understanding of what “innovations” are required for the public good is a question that needs to be answered today so that industry can develop the drug pipelines of tomorrow for the benefit of society.
Why this event?
• Discuss payers and policy makers views regarding their disease indications and public health investment priorities today and in the future.
• Understand what are the payer’s priorities to make long-term R&D investment decisions.
• Learn what are products that payers want to pay for and will generate return on investment.
• Help encourage medical “innovation” and to improve patient access to high-value medications and devices.
Who will benefit?
PAYERS & POLICY MAKERS: Senior representatives from Payers, health plans & insurers, Public health experts, health technology assessors, hospital financial management, government & health ministry officials, health management and managed care organizations, epidemiology, horizon scanning, scientific advice, pharmacy strategy & budget management.
INDUSTRY: Corporate senior management, strategic marketing, portfolio strategy & management, corporate & business development health economics, outcomes and market access, epidemiology, health policy, government and stakeholder relations, chief medical officers, R&D strategy, financial strategy.
OTHER STAKEHOLDERS: Regulatory agencies, key-opinion-leaders, independent health economists, health researchers and academics, physicians, patient groups.
To request the full agenda please follow the link:
For Booking Information contact:
Tel: +421 232 660 382
Fax: +421 2 3301 0331
Wednesday, July 6th, 2011
Conference Dates: February 1-2nd, 2012
Venue: Vienna, Austria
The roles of medical affairs and liaison have never before been so crucial to the success of pharmaceutical strategic and operational commercial objectives. Medical departments play a vital role in generating quality clinical and real-world data that payers and prescribers need to improve decision making when uncertainty is high. Technologies such as EDC on the trial-sponsor side and e-healthcare on the payer/provider side also offer opportunities to understand and treat disease in diverse patient populations, across all therapeutic areas. The medical affairs department is increasingly becoming central to the coordination of internal stakeholders with the needs of external stakeholders and achieving more client-centric business models. Clearly, the pharmaceutical industry’s traditional sales and marketing models and processes are no longer effective and medical teams are now required to largely fill the void. New ways to engage with tomorrow’s stakeholders are now required.
As payers are increasingly the “gatekeeper” in deciding if a health technology should be reimbursed at all, evidence generation to demonstrate cost-effective health outcomes has never before become so vital. However, best practice approaches have not been defined well and there is still much confusion as to the best way of designing and implementing such studies that can provide relatively unbiased information. Medical teams not only need to develop strong data, but also need to help educate KOLs and payers on the value of that data, especially for complex diseases.
Developing and providing expert medical insight can also deliver strategic direction, increase drug and disease understanding. With particular focus on relationships with payers, KOLs and prescribers, pharmacies and patient advocacy groups, and by working across a range of internal departments on projects there is the real possibility of leveraging this information to create a win-win: increase innovation, patient access and achieve improved budget-effective health outcomes.
• Understand how medical affairs are at the forefront of new pharmaceutical industry commercial models and what needs to be done to maximise success.
• Discover what are the most intelligent ways to engage with KOLs and other prescribers, payers, patient groups, pharmacies and tomorrow’s stakeholders.
• Benchmark with experts to find out what are best practices in late-phase research, especially observational studies, patient registries and investigator initiated studies.
• Discover how medical liaisons, in support of commercial teams, are crucial to the communication of effectiveness, safety and cost-effectiveness.
Who will benefit?
VPs, directors, managers of Medical Affairs, Medical Science Liaisons, Medical Education, Health Outcomes, & Economics, Medical Marketing, Lifecycle management, Product management, KOL & stakeholder engagement, Late Phase Clinical development, Field Sales, Medical Advisor
To request the full agenda please follow the link:
For Booking Information contact:
Tel: +421 232 660 382
Fax: +421 2 3301 0331
Monday, April 4th, 2011
With Indian healthcare sector currently witnessing its peak in terms of business potential and return on investment, the medical industry is expected to become a $ 280 billion industry by 2020 with spending on health estimated to grow by 14 per cent annually. However, despite the positive trends witnessed, India as a country, even after six decades of its political independence, is still struggling to address the healthcare needs of majority of its population. At the very outset, we have to acknowledge that the main problem in India’s health sector is not the unavailability of medicine and human resources, but their proper accessibility & distribution.
Recognizing the above trends in the Indian medical sector, INK Business Media Pvt Ltd, a leading conference production & management company would be organizing a two day conference – MediHealth Congress 2011-Redifining Innovation, Infrastructure & investment in Healthcare, with an aim to bring together the experts from the healthcare industry to identify, debate & come out with some feasible solutions to bridge the gaps in Indian medical system.
To be organized in Chennai on 5 May 2011, the focus of the conference would be on deriving competent strategies to achieve profitability for the investors and at the same time make healthcare accessible & affordable to the common man. Moreover, the focus would also be on business development, innovations in the healthcare sector, developing mobile healthcare, telemedicine & related technologies, and ways to enable healthcare facilities and consultancy reach remote areas.
What is in store?
At MediHealth Congress each delegate gets an opportunity to -
• Meet over 25+ word-class speakers
• Network with more than 250+ decision makers in the healthcare sector
• Visit concurrent exhibition
• Meet the technology manufacturers & suppliers and gauge the recent technology innovations
• Meet policy makers & leading health associations
• Attract international investors and much more.
Some of the sessions the forum intends to cover include effective business models for specialty & multispecialty hospitals in India; top management strategies in practice: Creating better healthcare delivery in hospitals; hospital Infrastructure: Importance in patient satisfaction & business growth; Dealing with technology adoption, finance & insurance issues in healthcare organizations; Innovations in medical technology: How important is it for a doctor to know & adopt; Telemedicine-effective platform for efficient healthcare delivery; Concept of Medicities/healthcities: How to make it a success in India; Medical Tourism-Way forward for India & globalization of Indian Healthcare; Healthcare Retail: An overview; Ethical & legal concerns in healthcare etc.
Advisory panel & speakers
The fact that this conference is being organized for the first time did little to deter the organizers from scheduling a robust line up of speakers & esteemed advisory board members for the event. The advisory panel of MediHealth Congress 2011 includes Dr Narottam Puri, Advisor – Medical, Fortis Healthcare Limited; Dr Prem Jagyasi, MD & CEO – ExHealth, Dubai HealthCare City, UAE; Mr Rajendra Pratap Gupta, International Healthcare & Retail Expert; and Dr Dev Taneja, Director – Indo American Hospitals. Apart from the advisory panel, about 15 other speakers have confirmed their presence at the event. For more details regarding confirmed speakers and detailed agenda for the co0nference, one can visit the event website – www.medihealthcongress.com.
Who can attend?
INK Business Media would be pleased to welcome Chairmen, Managing Directors, CEOs, Medical Directors, Directors, Business Development Heads, Head of Operations (department) etc from hospitals & clinics; individual medical professionals & practicing physicians as well as policy makers in the healthcare industry.
For more information about the Conference feel free to contact:
Wednesday, November 10th, 2010
Christian Haller from MPR Product Development, a solution provider at the marcus evans Medical Device R&D Summit 2010, shares his thoughts on the most effective product development planning strategies.
Interview with: Christian Haller, Director MPR Product Development
Las Vegas, NV, July 2, 2010 – FOR IMMEDIATE RELEASE
Medical device Research and Development (R&D) directors very often come up with brilliant product ideas but do not necessarily plan the development process properly, according to Christian Haller, Director MPR Product Development. They end up spending substantially more time and money developing a product than they really need to. A solution provider at the marcus evans Medical Device R&D Summit 2010 taking place in June 20-22, Haller discusses best practices for product development and risk management.
What long-term strategies and best practices would you recommend?
Christian Haller: One of our primary approaches is to manage risks; not only technical risks but product and development risks, such as marketing, reimbursement, and regulatory approval. In our experience, many companies do not put sufficient effort upfront into planning out a detailed vision of what the product is, how it is going to be used and paid for, the business case of the product from the buyer’s point of view, and the user experience. While mostly everyone gets around to these activities, much time and effort can be saved by spending more time up front on these issues.
Medical device R&D directors should take more time planning, talking to potential users to find out what they really want from the product, and identifying how the product fits into the business model, not only as a manufacturer but how it fits into the consumers’ business model. They need to focus on the final outcome as early on as possible. This will mean fewer changes in the development process. Very often, people come up with an initial idea but do not think through all of these issues and they have to continually redefine the image of the product. They spend more time re-developing the product and as a result, substantially more money than they really need to.
These strategies also help in decreasing the time to market. We have reduced our average time of filing very complex devices to a year or just under. Compared to industry averages, we are proud of this metric. Of course, you cannot guarantee how long the US Food and Drug Administration (FDA) will take to approve a product, but planning upfront and a proactive approach with the FDA helps speed things up.
What challenges are medical device R&D directors in North America facing?
Christian Haller: The market is focused on coming up with new products with fewer resources. Many companies are cutting R&D budgets ahead of the taxes on medical devices, which will be imposed by the Health Care Reform Bill. People will have to keep doing more with less, in addition to having to come up with products that work better in order to be approved for use by the Bill.
There are also significant modifications to the FDA rules which we are not used to; there are many unknowns in that regard. From our experience, it is important to take a cooperative and proactive approach with regulators. R&D directors should spend a lot of time on due diligence and determining the best regulatory strategies, going to the FDA with their plans, defining their own recommended regulatory path and working to build consensus upfront. You have to be your own advocate with the FDA. Talk early and talk often, is what we tell to our clients.
How can the product lifecycle be extended?
Christian Haller: In the effort to get to the market quicker, we advise clients not to add too many features that are not absolutely essential. We have found that one of the best ways to extend the lifecycle of a product is to define the architecture of the device, so that additional features and applications can be added cost effectively later on. By defining the architecture appropriately, you enable the ability to refresh the product at a later stage.
When outsourcing parts of the R&D process, how can manufacturers ensure everything is in sync?
Christian Haller: Firstly, they need a detailed written plan from all solution providers that covers the entire development process. When we start a project, we give the client a very detailed plan covering all the stages of the project, all the deliverables and activities defined, with a detailed listing of what will and will not be included. It is important to communicate that effectively. Everything should be written down, from beginning to end. The two parties have to reach complete agreement on the plan and the review process before starting.
Secondly, the parties have to establish regular scheduled meetings, perhaps once a week either in person or via teleconference, to walk through the status of the job.
Thirdly, it is necessary to have a team at the outsourced end that is dedicated, and a project manager who is constantly in contact with the client, who will oversee the project from beginning to end. The team at the outsourced company should be an extension of the manufacturer’s own development team.
Lastly, the way we see it, it is more efficient to have third party suppliers who can do the entire job. One could hire a software company, an electronics company, and a mechanical design company, but that generally means getting all those different outsourced resources working together harmoniously, often a full time job. Going to a company with a proven track record that is able to do the entire job is key. People will be more motivated to cooperate with each when there are fewer companies involved.
Contact: Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division
About the Medical Device R&D Summit 2010
This unique forum will take place at the Red Rock Casino Resort & Spa, Las Vegas, Nevada, June 20-22, 2010. Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The summit includes presentations on emerging technologies, speeding product development and addressing the challenges of outsourcing.
For more information please send an email to Jana Urbanovska at email@example.com or visit the event website at www.medicalrdsummit.com/media_GTM_ch
Please note that the summit is a closed business event and the number of participants strictly limited.
About marcus evans Summits
marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, think tanks, seminars and one-on-one business meetings. For more information, please visit www.marcusevans.com
All rights reserved. The above content may be republished or reproduced kindly inform us by sending an email to firstname.lastname@example.org
Sunday, December 6th, 2009
Conscious Sedation Consulting announces the development of a course to educate non-anesthesia physicians and nurses in the administration of propofol. The company announced that a comprehensive didactic course will be provided internationally for physicians, staff and organizations which wish to add propofol administration to their choice of sedatives. The course covers patient selection, a comprehensive detailed explanation of the pharmacology and pharmacokinetics of propofol, BIS monitoring, computer-controlled infusions, airway management, physiological monitoring, as well as the prevention, recognition and management of adverse events. Also covered are documentation, accreditation standards, patient recovery, discharge, follow up and process improvement. The seminar uses as a foundation, an understanding of a culture of safety as described by the Institute of Medicine in its report To Err is Human.
Propofol (2,6-diisopropyl phenol) is classified as an ultra-short-acting hypnotic agent that provides sedative, amnesic, and hypnotic effects. Propofol rapidly crosses the blood-brain barrier and causes a depression in consciousness that is likely related to potentiation of the g-aminobutyric acid A receptor in the brain.1 Propofol is 98% plasma-protein bound, and it is metabolized primarily in the liver by conjugation to its glucuronide and sulfate to produce water-soluble compounds that are excreted by the kidney. Typically, the time from injection to the onset of sedation is 30 to 60 seconds. Its duration of effect is 4 to 8 minutes. The pharmacokinetic properties do not significantly change in patients with renal failure or moderately severe chronic liver disease. Dose reduction is required in patients with cardiac dysfunction and in the elderly as a result of decreased clearance of the drug. Propofol potentiates the central nervous system effects of analgesics and sedatives such as benzodiazepines, barbiturates, narcotics, and other hypnotic/sedative agents. Therefore, the dose requirements of these agents may be reduced. The cardiovascular effects of propofol include decreases in cardiac output, systemic vascular resistance, and arterial pressure.2 Negative cardiac inotropy and respiratory depression can be seen with the use of propofol. These effects reverse rapidly with dose reduction or interruption of drug infusion3 and rarely require temporary ventilator support.
Controversy surrounds the use of Propofol by non-anesthesia providers. This is in part due to the FDA approved package insert which states that propofol should be administered by individuals trained in the administration of general anesthesia. Additionally some independent practitioners are either unwilling or unable to administer propofol due to local institutional policies or in some cases state regulatory restrictions. In spite of such concerns propofol use has seen a dramatic increase over the last decade. A 2006 study published by the American Journal of Gastroenterolgy reported that 68% of US endoscopists using conventional sedation indicate that they would prefer to administer propofol but are reluctant to do so because of widespread perception of increased complication risks.4 Propofol is more widely used in other countries.
John Hexem, MD, PhD, board certified anesthesiologist and co-founder of Conscious Sedation Consulting, LLC, stated â€œWhen used judiciously by physicians with specific training in the administration of propofol, it is a very nice drug. It has very favorable pharmacokinetic properties and patients regain full consciousness quickly, alert and comfortable. I have been administering propofol since 1991 and think it has definite advantages. Dr. Hexem also cautions that â€œproper monitoring and training that includes advanced airway management skills should be acquired prior to using this drug. Providers using propofol also need a thorough understanding of the continuum of sedation as described by the American Society of Anesthesiologists and national accrediting and safety organizations.
Since 2002 more than 500,000 subjects have received propofol for endoscopic sedation.5
From this data, propofol in appropriate patients with trained personnel has demonstrated an excellent safety record. Transient hypoxia occurs in 3% to 7% of cases and transient hypotension in 4% to 7%. Time to recovery ranged between 14 and 18 minutes. In a retrospective review of Nurse Administered Propofol Sedation (NAPS) in several centers and involving greater than 36,000 endoscopies, the rate of clinical adverse events, defined as apnea or airway compromise that required assisted ventilation via bag-mask, ranged from 0.1% to 0.2%. 6 No patients required intubation, and none had permanent injury or death.
For additional information please visit online at www.SedationConsulting.com
Or call at 1.888.581.4448.
About: Conscious Sedation Consulting LLC, a patient safety advocacy firm that provides continuing education, training and consulting services to non anesthesia health care providers who offer sedation and analgesia services.
Statement of Disclosure: It is the policy of Conscious Sedation Consulting LLC, its principles and any of its employees to disclose any financial interest or other relationship with a commercial interest producing healthcare goods or services that has a direct bearing on the subject matter of any educational activity. A relevant financial interest or other relationship may include such things as grants or research support or a relationship such as an employee, consultant, major stockholder, member of speaker’s bureau, and the like, that has been established for any dollar amount over the past 12 months. We have nothing to disclose.
Conscious Sedation Consulting LLC
27 Forest Lane
Ofallon, MO 63366
1) Trapani G, Altomare C, Liso G, et al. Propofol in anesthesia: mechanism of action, structure-activity relationships, and drug delivery. Curr Med Chem 2007;7:249-71.
2) White PF. Propofol pharmacokinetics and pharmacodynamics. Semin Anesth 1988;7:4-20.
3) Short TG, Plummer JL, Chui PT. Hypnotic and anaesthetic interactions between midazolam, propofol and alfentanil. Br J Anaesth 1992;69: 162-7.
4) Cohen LB, Wecsler JS, Gaetano JN, et al. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol 2006;101:967-74.
5)Cohen LB, Hightower CD, Wood DA, et al. Moderate level sedation during endoscopy: a prospective study using low-dose propofol, meperidine/fentanyl, and midazolam. Gastrointest Endosc 2004;59: 795-803.
6) Rex DK, Heuss LT, Walker JA, Qi R. Trained registered nurses/endoscopy teams can administer propofol safely for endoscopy. Gastroenterology 2005;129:1384-91.
Monday, May 25th, 2009
New York, NY, May 26, 2009 â€“ IIR, the world’s leading knowledge and skills transfer company, is pleased to announce the former Senator Tom Daschle as keynote speaker of the 14th Annual Summit on the Medicaid Drug Rebate Program, September 21-23, 2009, Chicago, IL.
One of the most influential men in Washington today, Tom Daschle is a former senator whose lifelong passion and commitment to public service and healthcare reform is undeniable. As Senate majority and minority leader from 1994 2005 and the architect of President Obama’s healthcare plan, he is an outspoken advocate for reform, and a well-connected voice between the healthcare industry and Washington policy-makers. His recent book, Critical: What We Can Do About the Healthcare Crisis, offers exciting new solutions on changing America’s healthcare system which provides the framework for Obama’s plan. Senator Daschle is also actively involved in the Bipartisan Policy Center, with Senators Howard Baker, Bob Dole, and George Mitchell, and in both the public and private sector, remains dedicated to finding common ground between conservatives and liberals on the issues that impact us all.
Anne Reel, the Director of IIR’s 14th Annual Medicaid Drug Rebate Summit, says, the pharmaceutical manufacturers are keenly interested in how the current political landscape will change, especially how these changes affect Medicaid reimbursements. Tom Daschle can help the manufacturers understand the new solutions to changing America’s healthcare system and provide the framework for Obama’s Plan. The manufacturers have devoted more internal resources to adapt to new MDRP processes resulting from the DRA and are incurring increased costs due to pending litigations and planning compliance strategies. With insights gathered from our Advisory Board and intensive market research, our annual three-day summit continues to be the top destination for key pharmaceutical manufacturers, state Medicaid professionals, attorneys, experienced consultants, government agency representatives, enforcement agencies, legislative and policy groups.
About the Medicaid Drug Rebate Program Summit
The Medicaid Drug Rebate Program Summit, created and developed by IIR, is the Nation’s largest cross-functional Rebate Program Summit offering CMS representatives explaining implementation strategies for DRA compliance, OIG describing lessons learned from current litigations, updated information by NACDS detailing the AMP litigation, organized dispute resolution meetings facilitated by CMS and more.
The event is designed for Pharmaceutical Manufacturers Managers and Directors working in Medicaid Rebates, Government Affairs and Contracting, Public Policy, Pricing, Finance/Accounting, Sales/Marketing, Legal Counsel, Pharmacy, Accountant, Pharmacy Contracts and Rebates. To learn more about this event, please visit: www.medicaiddrugrebates.com
IIR is the world’s leading knowledge and skills transfer company with a global network of 47 companies and 112 operating units. Every year, IIR works with 650,000+ business executives providing them with knowledge and skills through training, conferences, seminars, e-Learning, blended solutions, exhibitions, consulting and mentoring. To learn more about IIR, please visit www.iirusa.com.
Wednesday, April 1st, 2009
Worldwide medical tourism has grown over recent years beyond all expectations and is entering a new phase where key issues and questions are being raised not only by the travelling patients but also by government health ministries, public and private hospitals, facilitators, medical organisations, international corporations and insurance companies all over the world.
The Malta Medical Tourism Summit will address these concerns from a global perspective and provide a platform for discussion from all sectors of the medical tourism industry.
The summit will comprise a full two day conference programme featuring international speakers presenting on topics includingÂ Â â€“
Â·Â Â Â Â Â Â Â Â The structure and dynamics of the global medical tourism marketplace
Â·Â Â Â Â Â Â Â Â Improving the image and marketing of medical tourism
Â·Â Â Â Â Â Â Â Â Implications of implementing cross border health collaborations
Â·Â Â Â Â Â Â Â Â The impact of current EU directives on the medical tourism industry
Â·Â Â Â Â Â Â Â Â Why Malta is ready to play a greater part in medical tourism
Â·Â Â Â Â Â Â Â Â Risks associated with medical tourism and who regulates the industry
Â·Â Â Â Â Â Â Â Â The role of the insurer in medical tourism and what can be done to improve this
In addition there will be ample time set aside for networking and discussion. The exhibition area will provide a meeting and networking area during refreshment breaks and lunches and there will also be a poolside drinks reception and gala dinner on the first evening.
Who will attend?
The Malta Medical Tourism Summit will attract a global audience from the following sectors â€“
Â·Â Â Â Â Â Â Â Â Medical Tourism facilitators and travel agencies
Â·Â Â Â Â Â Â Â Â Private & public hospitals
Â·Â Â Â Â Â Â Â Â Clinics
Â·Â Â Â Â Â Â Â Â Medical organizations and associations
Â·Â Â Â Â Â Â Â Â Destination tourism ministries and promotion boards
Â·Â Â Â Â Â Â Â Â Health and travel insurance providers
Â·Â Â Â Â Â Â Â Â Hotels & Resorts with special health facilities
Â·Â Â Â Â Â Â Â Â Government health ministries
Â·Â Â Â Â Â Â Â Â Spas and after facilities
Â·Â Â Â Â Â Â Â Â Global corporations
As well as focusing on key issues within the medical tourism industry the summit will highlight Malta as a destination for medical tourists. Maltaâ€™s healthcare system was recently ranked fifth in the world and historically Malta has strong links with medical tourism and is proud of its historicalÂ reputation as the â€˜the hospital of the Mediterraneanâ€™. Together with its central location and temperate climate Malta has world class hospitals and clinics as well as excellent aftercare and recuperation facilities.
Exhibiting and Sponsorship
In the exhibition area attending companies and organisations will be able to showcase their products and services and this will also serve as the networking focal point of the summit during refreshment breaks and lunches. In addition the conference offers numerous sponsorship and branding opportunities which can be tailored to suit your personal budget and requirements.
The Hilton Hotel is situated at the heart of the fashionable PortomasoÂ waterfront and is also onlyÂ 15 minutesâ€™ drive from Valletta and 20 minutes drive from Malta International Airport. The hotel offers excellent purpose built conference facilities, international cuisine, business centre, in room internet connection and wonderful views of the Mediterranean.
Wednesday, March 25th, 2009
How interested are you to gain preferential market access via innovative payer agreements?
NextLevel Pharma is organising the only meeting looking at risk-sharing and value-based pricing and reimbursement schemes.
Achieving preferential market-access through innovative agreements with payers
( Brussels, Belgium, 23rd- 24th April, 2009)
This will be an ideal opportunity to understand and learn from the experiences and opinions of other pharma and medical devices companies, HTA agencies, payers and keystakeholders and benchmark globally.
Find your reasons to Attend:
- Understand what are the most up to date, innovative agreement solutions and future trends in different countries globally
- Learn how drug effectiveness, value and safety are being demonstrated in deferent regions.
- Benchmark, network and co-operate with policy makers and key, influential figures. Get the best and most focused picture of risk-sharing and value-based pricing models today.
- Hear the perspectives of all stakeholder groups: Ministries of Health, HTA Agencies, Insurers, Doctors, Patients and Patient Groups, Health Economists and the Pharmaceutical Industry.
- Discover how payers are evaluating a range of complex pricing and reimbursement agreements.
- Understand what patients want and what they define as a quality treatment, that enhances their lives.
- Find out if risk-sharing and value-based pricing schemes can help pharma and medical device manufactures achieve preferential
- market access and a competitive advantage.
- Understand the best ways to comunicate value with stakeholders and achieve maximum patient and market access.
GlaxoSmithKline, UK- Director Global Health Outcomes, Oncology
Novartis, Switzerland- Global Brand Pricing & Reimbursement Director
Astellas, UK- Vice President, Medical Affairs & Health Economics Europe
Medtronic- Director, Reimbursement and Health Economics, Central and Eastern Europe, Greece and Israel
Indiana Office of Medicaid Planning and Policy, USA- Director, Health Quality, Policy Research and Strategic Planning
OHE, UK- Director of the Office of Health Economics
NHS Innovations London- Head of Health Outcomes Unit
Tufts Center for the Study of Drug Development, USA- Associate Director
Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices
Oncology Center Antwerp- Director
Tufts Center for the Study of Drug Development, USA- Associate Director
Luiss University & Business School, Rome- Healthcare and Pharmaceutical Economics and Polices
Oncology Center Antwerp- Director
Together, they will deliver knowledge, expertise, insights, opinions, facts and data that can add strategic intelligence and real-value to your business.
To request the agenda, registration form and to learn more about this event, please follow the link:
In case you have any problems with link, please contact me directly and I will send the agenda to you immediately.
MARKET ACCESS STRATEGIES FOR PERSONALISED MEDICINES
AND COMPANION DIAGNOSTICS
BUILDING VALUE-PROPOSITION AND BUSINESS MODEL TO REALISE THE FULL COMMERCIAL POTENTIAL OF PERSONALISED HEALTHCARE
(Brussels, April 21-22nd April)
ph: +421 2 3266 2621
fax: +421 2 3266 0395
Thursday, February 28th, 2008
Officially supported by SingaporeMedicine and organized by IBC Asia, the 2nd Annual Medical Tourism Asia Conference will be held from the 25th to the 28th March 2008 at the Rasa Sentosa Resort. It is expected to gather top-level professionals from health ministries, healthcare institutions, insurers, medical travel agencies and other key buyers in the global healthcare market.
Rising healthcare costs in the United States and Europe are causing patients to rethink seeking medical treatment at their doorstep. With 44.8 million Americans uninsured and millions more under insured, the global market for medical tourism and travel is set to grow even more exponentially in the next 5 years. Not only are cost savings in medical travel tremendous, the access to affordable quality treatment, level of success rates, shorter waiting times, more personalized attention in the recovery process are all causative reasons in a patient’s decision to select the best healthcare facility that will address his medical needs.
Medical Tourism Asia 2008 will address the following key issues:
* Charting the course of medical travel for long-term sustainability
* Updates from the various Asian and international markets active in medical tourism
* Building on health and wellness resorts and medical spas as an additional business stream
* Branding and marketing medical travel for your country and healthcare institution
* Addressing medical insurance for the traveling patient
* Healthcare Cities’ and their future development
* Obtaining accreditation for hospitals
* Healthcare professionalism and ensuring patient safety throughout his entire treatment
Keynote Speakers for Medical Tourism Asia 2008 include:
* Prof Tan Ser Kiat, Group CEO, SingHealth
* Dr Jade del Mundo, Undersecretary of Health, Department of Health, Philippines
* Sangita Reddy, Executive Director, Apollo Hospitals, India
* Dr Fatma Abdullah, Chief Strategy Officer, Dubai Healthcare City
* Dr Walton Li, Medical Superintendent, Hong Kong Sanatorium and Hospital
* Dr Jason Yap, Director, Healthcare, Singapore Tourism Board
* Arturo Garza, CEO, Christus Muguerza, Mexico
* Dr Saw Chit Aung, Deputy Director, Hospital Marketing, Raffles Medical Group
* Dr Jorge Cortes Rodriguez, Medical Director, Hospital Clinica Biblica, Costa Rica
* Dr Surapong Ambhanwong, Chief Medical and International Business Officer, Phyathai Group of Hospitals
* Christine Liwanag, Senior VP, Strategic Marketing, St Lukeâ€™s Medical Centre, Philippines
* Chew Boon Yeow, Group VP, Risk Management, Parkway Healthcare
* Dr William Chong, CEO, Pacific Healthcare Holdings
* Dr Chan Kok Ewe, CEO, Island Hospital, Malaysia
About the organiser: IBC is part of the Informa Group, with offices in over 30 countries and is the world’s largest organiser of top-level industry conferences, exhibitions and training. It has a dedicated portfolio of events for the healthcare and life sciences sectors, bringing together senior representatives from the private sector, government authorities and international organizations.
For media inquiries and registration for the conference, kindly contact Rita Parasurum at email@example.com or call +65 68355160. Visit www.medicaltourism-asia.com for more information today!